Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KeyGen-GPC3
- Development stage
- Preclinical
- Lead developer
- Beijing KeyGen Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KeyGen-GPC3 is a therapeutic development program by Beijing KeyGen Biotech targeting Glypican-3 (GPC3), a cell-surface oncofetal antigen that is highly expressed in hepatocellular carcinoma (HCC) but absent in normal adult liver tissue. The program encompasses both a GPC3-targeting monoclonal antibody and an antibody-drug conjugate (ADC) derived from it. The monoclonal antibody is designed to bind specifically to GPC3-expressing tumor cells, potentially mediating anti-tumor effects through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) or interference with GPC3-mediated signaling pathways. The ADC variant utilizes the antibody's high specificity to deliver a cytotoxic payload directly into the cancer cells upon internalization, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. Currently in the preclinical stage, these assets are being developed as targeted therapies for the treatment of GPC3-positive hepatocellular carcinoma.
- Other names
- Beijing KeyGen GPC3-mAbBeijing KeyGen GPC3-ADCGPC3 monoclonal antibody/ADC
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on KeyGen-GPC3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KeyGen-GPC3.